Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Non Operating Income (2020 - 2025)

Apellis Pharmaceuticals has reported Non Operating Income over the past 6 years, most recently at -$151000.0 for Q4 2025.

  • Quarterly results put Non Operating Income at -$151000.0 for Q4 2025, up 91.44% from a year ago — trailing twelve months through Dec 2025 was -$133000.0 (up 93.87% YoY), and the annual figure for FY2025 was -$133000.0, up 93.87%.
  • Non Operating Income for Q4 2025 was -$151000.0 at Apellis Pharmaceuticals, down from $37000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for APLS hit a ceiling of $50.3 million in Q4 2022 and a floor of -$1.8 million in Q4 2024.
  • Median Non Operating Income over the past 5 years was -$32500.0 (2021), compared with a mean of $2.4 million.
  • Biggest five-year swings in Non Operating Income: plummeted 1320.0% in 2021 and later soared 1256625.0% in 2022.
  • Apellis Pharmaceuticals' Non Operating Income stood at -$4000.0 in 2021, then soared by 1256625.0% to $50.3 million in 2022, then tumbled by 99.56% to $219000.0 in 2023, then tumbled by 905.94% to -$1.8 million in 2024, then soared by 91.44% to -$151000.0 in 2025.
  • The last three reported values for Non Operating Income were -$151000.0 (Q4 2025), $37000.0 (Q3 2025), and $146000.0 (Q2 2025) per Business Quant data.